

Phase III COPD Studies

Study Basics

- **Disease:** Chronic Obstructive Pulmonary Disease
- **Phase:** III
- **Target Geography:** Global
- **Total Number of Sites:** 565

Background

A top sponsor was facing new and lingering challenges from the COVID-19 pandemic resulting in a slow & difficult patient recruitment process on two COPD trials. In order to overcome these challenges and hit their newly established diversity targets, the sponsor partnered with Inato.

The Problem

The sponsor was facing challenges in these trials, particularly with identifying sites that could hit enrollment targets and had access to underrepresented minority populations. Overall, COPD trials were struggling due to the pandemic and its lasting impact. Many of the large academic centers that the sponsor traditionally relied on for these trials were redirected away from research. Additionally, COPD wasn't exacerbating due to COVID protocols. These combining factors led to a very slow and difficult patient recruitment process. With rising pressure to hit trial targets, including, for the first time, specific diversity targets, the sponsor turned to Inato.

85%

OF THE
PARTICIPANTS
ENROLLED ON
INATO WERE
DIVERSE

AND

SITES ACHIEVED

95%

OF INATO'S
VERIFIED
COMMITMENT




The Solution

By collaborating with Inato, the sponsor was able to open applications to a broad range of experienced COPD sites. These community-based sites were less impacted by the pandemic and able to use their deep relationships in the community to quickly recruit and enroll typically underserved patients.

In total, 24 sites were activated through Inato, allowing the sponsor to find exactly what they were looking for: **low competition, diversity, and fast start up times.**

Inato sites delivered a target demographic



In the end, Inato sites...

Globally enrolled

0.3 pts/site/month

vs. 0.2 pts/sites/month at
non-Inato sites

AND

In the US, enrolled

0.3 pts/site/month

vs. 0.1 pts/sites/month at
non-Inato sites

Interested in finding the right sites for your trial?

Reach out today at contact@inato.com